• Kurtis D Davies, Anh T Le, Mariana F Theodoro, Margaret C Skokan, Dara L Aisner, Eamon M Berge, Luigi M Terracciano, Federico Cappuzzo, Matteo Incarbone, Massimo Roncalli, Marco Alloisio, Armando Santoro, D Ross Camidge, Marileila Varella-Garcia, and Robert C Doebele.
• Division of Medical Oncology, University of Colorado, MS 8117, 12801 E. 17th Ave, Aurora, CO 80045, USA.
• Clin Cancer Res. 2012 Sep 1; 18 (17): 4570-9.

PurposeOncogenic gene fusions involving the 3' region of ROS1 kinase have been identified in various human cancers. In this study, we sought to characterize ROS1 fusion genes in non-small cell lung cancer (NSCLC) and establish the fusion proteins as drug targets.Experimental DesignAn NSCLC tissue microarray (TMA) panel containing 447 samples was screened for ROS1 rearrangement by FISH. This assay was also used to screen patients with NSCLC. In positive samples, the identity of the fusion partner was determined through inverse PCR and reverse transcriptase PCR. In addition, the clinical efficacy of ROS1 inhibition was assessed by treating a ROS1-positive patient with crizotinib. The HCC78 cell line, which expresses the SLC34A2-ROS1 fusion, was treated with kinase inhibitors that have activity against ROS1. The effects of ROS1 inhibition on proliferation, cell-cycle progression, and cell signaling pathways were analyzed by MTS assay, flow cytometry, and Western blotting.ResultsIn the TMA panel, 5 of 428 (1.2%) evaluable samples were found to be positive for ROS1 rearrangement. In addition, 1 of 48 patients tested positive for rearrangement, and this patient showed tumor shrinkage upon treatment with crizotinib. The patient and one TMA sample displayed expression of the recently identified SDC4-ROS1 fusion, whereas two TMA samples expressed the CD74-ROS1 fusion and two others expressed the SLC34A2-ROS1 fusion. In HCC78 cells, treatment with ROS1 inhibitors was antiproliferative and downregulated signaling pathways that are critical for growth and survival.ConclusionsROS1 inhibition may be an effective treatment strategy for the subset of patients with NSCLC whose tumors express ROS1 fusion genes.©2012 AACR.

47 keywords...

hide…